October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
September 30, 2024 C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies C-Path announced the formation of a new task for under its RDCA-DAP, dedicated to...
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
October 23, 2024-October 27, 2024 American Society of Nephrology (ASN) Kidney Week 2024 BmDR Oversight Committee members Nicholas King, Katrina Peron, and Gary Friedman will be attending ASN Kidney Week 2024 in....
August 22, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project in Prostate Cancer C-Path proudly announced today a $250,000 grant award to Peter Wipf, Ph.D...
August 1, 2024 Advancing Rare Disease Measurement With The Rare Disease COA Resource It is estimated that more than 350 million people worldwide live with a rare disease.
Evidence-Based Treatment Decisions In Transplantation: The Right Dose & Regimen for the Right Patient/Individualized Treatment The following originally appeared on fda.gov: Summary: The Food and Drug Administration is announcing the following public worksho
Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker Tucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (E
C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS) Tucson, AZ – December 18, 2017 Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
